Page last updated: 2024-10-24

buspirone and Esophageal Dysmotility

buspirone has been researched along with Esophageal Dysmotility in 3 studies

Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.

Research Excerpts

ExcerptRelevanceReference
"Buspirone is a serotonin modulating medication and has been shown to augment esophageal peristaltic amplitude in healthy volunteers."2.87A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility. ( Aggarwal, N; Gabbard, S; Lopez, R; Thota, PN, 2018)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aggarwal, N1
Thota, PN1
Lopez, R1
Gabbard, S1
Karamanolis, GP1
Panopoulos, S1
Denaxas, K1
Karlaftis, A1
Zorbala, A1
Kamberoglou, D1
Ladas, SD1
Sfikakis, PP1
Blonski, W1
Vela, MF1
Freeman, J1
Sharma, N1
Castell, DO1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)[NCT02363478]Early Phase 122 participants (Actual)Interventional2014-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes From Baseline in Manometric Parameters: Duration of Contractions at the Distal Part of the Esophagus at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Interventionsec (Mean)
Buspirone0.5

Changes From Baseline in Manometric Parameters: Velocity of Contractions at the Distal Part of the Esophagus at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Interventioncm/sec (Mean)
Buspirone0.3

Changes From Baseline in Manometric Parameters: i) Amplitude of Contractions at the Distal Part of the Esophagus and ii) Resting and Residual (Lower Esophageal Pressure) LES Pressure and IRP (Integrated Relaxation Pressure) at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

InterventionmmHg (Mean)
amplitudeLES resting pressureLES residual pressureIRP
Buspirone0.94.50.30.4

Changes in the Severity of Esophageal Symptoms at Week 4

Severity of esophageal symptoms (dysphagia, heartburn, regurgitation and chest pain) was measured on a 100-point visual analogue scale (VAS) ranging from 0 (absent) to 100 (very severe). Even minor decrease in the VAS score for each symptom at week 4 considered as improvement. (NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Interventionunits on a scale (Mean)
heartburnregurgitationdysphagiachest pain
Buspirone14.913.26.91.9

Trials

3 trials available for buspirone and Esophageal Dysmotility

ArticleYear
A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility.
    Neurogastroenterology and motility, 2018, Volume: 30, Issue:2

    Topics: Buspirone; Cross-Over Studies; Double-Blind Method; Esophageal Motility Disorders; Female; Humans; M

2018
The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial.
    Arthritis research & therapy, 2016, 09-01, Volume: 18

    Topics: Adult; Aged; Buspirone; Esophageal Motility Disorders; Esophagus; Female; Humans; Male; Manometry; M

2016
The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers.
    Journal of clinical gastroenterology, 2009, Volume: 43, Issue:3

    Topics: Administration, Oral; Adult; Bethanechol; Buspirone; Cholinesterase Inhibitors; Cross-Over Studies;

2009